<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658214</url>
  </required_header>
  <id_info>
    <org_study_id>D419SC00001</org_study_id>
    <nct_id>NCT02658214</nct_id>
  </id_info>
  <brief_title>Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following
      indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will screen approximately 100 patients in order to have a total of approximately
      80 evaluable patients in 5 cohorts of first-line chemotherapy regimens combined with
      durvalumab + tremelimumab.

      This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab
      in combination with first line chemotherapy regimens in patients with locally advanced or
      metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma
      of the head and neck (SCCHN), triple negative breast cancer (TNBC), small cell lung
      carcinoma (SCLC), and gastric/gastro-esophageal junction (GEJ) cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Laboratory findings (including: clinical chemistry, hematology, and urinalysis)</measure>
    <time_frame>Throughout the study, approximately two years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety and tolerability profile of first-line chemotherapy in combination with durvalumab + tremelimumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Throughout the study, approximately two years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess incidence of Adverse Events for the safety and tolerability profile of first-line chemotherapy in combination with durvalumab and tremelimumab</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Triple Negative Breast Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <condition>Esophagogastric Junction Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Small-cell lung cancer (SCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple-negative breast cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple-negative breast cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric/gastro-esophageal junction (GEJ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel + carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin + etoposide</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine + carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel (paclitaxel-albumin) + carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)</intervention_name>
    <description>IV infusion and bolus administration</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>durvalumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Medi-4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tremelimumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age ≥18 years at the time of screening 2. Written informed consent and any locally
        required authorization 4. Patients with histologically or cytologically documented
        chemotherapy-naive locally advanced unresectable or metastatic
        ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC, and gastric cancer/GEJ.

        4a. SCCHN patients who are candidates for definitive chemoradiation are not eligible to
        participate.

        4b. Gastric/GEJ cancer is defined as HER-2 negative adenocarcinoma (not eligible for
        anti-HER-2 therapy).

        5. ECOG performance status of 0 or 1 6. At least 1 lesion, not previously irradiated, that
        can be accurately measured at baseline 7. No prior exposure to immune-mediated therapy 8.
        Adequate organ and marrow function

        Exclusion Criteria:

          1. Receipt of any investigational anticancer therapy within 28 days or 5 half-lives,
             whichever is longer, prior to the first dose of study treatment

          2. Brain metastases or spinal cord compression unless asymptomatic or treated and stable
             off steroids and anti-convulsants for at least 1 month prior to study treatment

          3. Any unresolved Grade ≥2 toxicity from previous anticancer therapy

          4. Active or prior documented autoimmune or inflammatory disorders

          5. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric
             illness/social situations that would limit compliance with study requirement,
             substantially increase risk of incurring AEs from study drugs, or compromise the
             ability of the patient to give written informed consent

          6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms
             20. Active tuberculosis

          7. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus
             (HIV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Khelif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GRU Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>durvalumab, MEDI4736, tremelimumab, small-cell lung, head and neck, triple negative breast, gastric/GEJ or ovarian cancer, immuno oncology, first-line chemo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
